LIM/31 - Laboratório de Genética e Hematologia Molecular

O Laboratório de Genética e Hematologia Molecular é ligado ao Departamento de Clínica Médica da Faculdade de Medicina da Universidade de São Paulo (FMUSP).

Linhas de pesquisa: Genética e hematologia molecular; terapia celular e gênica; onco-hematologia; hemostasia; metabolismo lipídico.

Site oficial: http://limhc.fm.usp.br/portal/lim31-laboratorio-de-genetica-e-hematologia-molecular/

Browse

Recent Submissions

  1. COVID-19 in chronic myeloid leukemia patients in Latin America

    LEUKEMIA & LYMPHOMA, v.62, n.13, p.3212-3218, 2021

    This observational, multicenter study aimed to report the clinical evolution of COVID-19 in patients with chronic myeloid leukemia in Latin America. A total of 92 patients presented with COVID-19 between March and December 2020, 26% of whom were severe or critical. The median age at COVID-19 diag...

  2. Challenges in Chronic Myeloid Leukemia Management in South America

    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, v.16, n.5, p.440-447, 2021

    Purpose of Review Chronic myeloid leukemia (CML) management in developing countries has improved in the last years, but the availability of therapeutic resources, monitoring, reimbursement, and financial issues may be a challenge and interfere with the best practices and results of CML treatment....

  3. Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation

    HEMATOLOGY TRANSFUSION AND CELL THERAPY, v.43, suppl.2, p.S54-S63, 2021

    Currently, there are four CAR-T products commercially available on the market. CAR-T cells have shown high remission rates and they represent an effective treatment option for patients with resistant or refractory B cell malignancies. Approval of these cell therapy products came after an extended...

  4. Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients

    HEMATOLOGY TRANSFUSION AND CELL THERAPY, v.43, suppl.2, p.S30-S34, 2021

    Extraordinary progress has been made over the last decade in the treatment of multiple myeloma with the incorporation of new drugs, particularly proteasome inhibitors, immunomodulators, and monoclonal antibodies. The combined use of innovative drugs, already in the first lines of treatment, has l...

  5. Quantification of airborne SARS-CoV-2 genomic particles in different hospital settings

    SCIENTIFIC REPORTS, v.11, n.1, article ID 21284, 6p, 2021

    We quantified the presence of SARS-CoV-2 RNA in the air of different hospital settings and the autopsy room of the largest medical centre in Sao Paulo, Brazil. Real-time reverse-transcription PCR was used to determine the presence of the envelope protein of SARS-CoV-2 and the nucleocapsid protein...

  6. Airborne microplastics and SARS-CoV-2 in total suspended particles in the area surrounding the largest medical centre in Latin America

    ENVIRONMENTAL POLLUTION, v.292, article ID 118299, 8p, 2022

    Microplastics (MPs) have been reported in the outdoor/indoor air of urban centres, raising health concerns due to the potential for human exposure. Since aerosols are considered one of the routes of Coronavirus disease 2019 (COVID-19) transmission and may bind to the surface of airborne MPs, we h...

  7. Amyloid Cardiomyopathy Establishing a Patient Referral Center in Brazil

    JACC: CARDIOONCOLOGY, v.3, n.4, p.606-610, 2021

  8. Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies

    HEMATOLOGY TRANSFUSION AND CELL THERAPY, v.43, suppl.2, p.S46-S53, 2021

    Chimeric Antigen Receptor T (CAR-T) cells are certainly an important therapy for patients with relapsed and/or refractory hematologic malignancies. Currently, there are five CAR-T cell products approved by the FDA but several research groups and/or biopharmaceutical companies are encouraged to de...

  9. Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia

    HEMATOLOGY TRANSFUSION AND CELL THERAPY, v.43, suppl.2, p.S13-S21, 2021

    Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cy...

  10. Carbapenem-resistant Klebsiella pneumoniae colonization and infection is associated with lower overall survival in a cohort of haematopoietic stem-cell transplantation patients: mechanism of resistance and virulence by whole-genome sequencing

    JOURNAL OF MEDICAL MICROBIOLOGY, v.70, n.10, article ID 1422, 6p, 2021

    Carbapenem-resistant Klebsiella pneumoniae (CRK) infections are a growing concern in immunocompromised patients. The aim of the present study was to evaluate the impact of CRK colonization and infection in overall mortality for haematopoietic stem-cell transplant (HSCT) patients. We also aimed to...